Mesothelioma of the Pleura - Photodynamic Therapy

Photodynamic therapy of malignant mesothelioma of pleura

Questions about mesothelioma or asbestos? ASK US NOW

4. DISCUSSION

Single modality therapeutic management has yielded few long-term survivors in malignant pleural mesothelioma. The role of surgery is generally considered to be limited. Pleurectomy/decortication is an incomplete tumour-debulking procedure and therefore ineffective as a single treatment with curative aim.

Extensive surgery by EPP has been advocated as a theoretically more attractive operation because it may allow a radical excision, but only a minority of patients with mesothelioma qualify for this operation and it carries a higher risk. Studies have shown that patients undergoing EPP have a greater tendency towards development of distant diseasel6. The therapeutic challenge is two-fold, effective treatment regimens for malignant mesothelioma must address the problem of systemic disease as well in order to obtain local and systemic control of the malignancy. Combined treatment modality appears to offer some promise in this otherwise rapidly fatal diseasel7.

The impact of the presented method in a small and heterogeneous patient group is difficult to evaluate. However, patients no. 2 and 6 reoperated a year after initial treatment were completely free from tumour within the thoracic cavity. During the follow-up, in 3 patienes distant metastases.were seen prior to recurrency within the treated hemithorax. Such results of relatively long-lasting local control were obtained in patients undergoing various surgical procedures with low mortality/morbidity. The tumours of these patienes presented photosensitizer Suorescence of even distribution and of high intensity. Patients with tumours of inhomogenious (related to the differentiation grade) and low fluorescence intensities showed rapid recurrency and metastases.

Patient no. 6, presenting a relatively high nuorescence intensity of the initial tumour and a significantly lower intensity in the metastatic tumour, showed generalized malignancy only 3 months after retreatment.

An approach by thoracoscopic PDT13 was considered not useful in these patients all of whom presented tumour masses of large size located in the costophrenic sulcus. CT scans did not offer sufficent accuracy to evaluate tumour thickness, especially in the costophrenic sulcus. We experienced improved surgical radicality as well as improved access for light exposure in this area by doing complete diaphragmatic resection.

As a conclusion we present the hypothesis that associated PDT-treatment has a clinical effect and that predictability of PDT-efficiency seem to be related to the distribution and intensity of the fluorescence induced by the photosensitiser in tumour (Table 1). The PDT-effect may enhance the potential to complete local tumour eradication even in the case of less aggressive surgical debulking procedure. However, as clearly visualized in this study a multimodal therapeutic approach addressing to the systemic disease seems necessary to further improve survival.

5. ACKNOWLEDGMENT

This study was finacially supported by The Norwegian Cancer Society. Photosensitiser and some of the technical equipment was a gift from Lederle, American Cyanamid.

6. REFERENCES

1. J.C. Wagner, E.A. Sleggs and P. Marchand, "Diffuse pleural mesothelioma and asbestos exposure in the North Western Cape Province," Br. J. Int. Med., 17, pp. 260-271, 1960.

2. K.H. Antman, P.F. Li, R. Osteen et al., "Mesothelioma," Cancer Updates, 3, pp. 1-16, 1989.

3. A.S. Alberts, G. Falkson, L. Goedhals, D.A. Vorobiof and C.A. Van Der Merwe, "Malignant pleural mesotheoioma: a disease unaffected by current therapeutic maneuvers," J. Clin. Oncol., 6, pp. 527-534, 1988.

4. L.W. Brady, "Mesothelioma - the role for radiation therapy," Semin. Oncol., 8, pp. 329-334, 1981.

5. S.L. Marcus, "Clinical photodynamic therapy: The continuing evolutibn," Photodynamic therapy; basic principles and clinical apSicatimnS, B.W. Henderson and TJ. Dougherty (eds.), pp. 219-2684 Marcel Dekker, Inc., New York, 1992.

6. TJ. Dougherty and S.L. Marcus, "Photodynamic therapy," Eur. J. Cancer, 28A, pp. 1734-1742, 1992.

7. TJ. Dougherty, "Photodynamic therapy," Photochem. Photobiol., 58, pp. 895-900, 1993.

8. J. Moan and K. Berg, "Photochemotherapy of cancer: Experimental research," Photochem. Photobiol., 5S, pp. 931-948, 1992.

9. B.W. Henderson and T.J. Dougherty, "How does photodynamic therapy work?" Photochem. Photobiol., 55, pp. 145-157, 1992.

10. K.R. Weishaupt, C.J. Gomer and T.J. Dougherty, "Identification of singlet oxygen as the cytotoxic agent in the photoactivation of a murine tumour," Cancer res., 36, pp. 2326-2329, 1976.

11. S.L. Gibson, T.H. Foster, R.H. Feins, R.F. Raubertas, M.A. Fallon and R. Hill, "Effects of Photodynamic therapy on xenografts of human mesothelioma and rat mammary carcinoma," Br. J. Cancer, 69, pp. 473-481, 1994.

12. R.H. Feins, R. Hilf, H. Ross and S.L. Gibson, "Photodynamic therapy for human malignant mesothelioma in the nude mouse," J. Surg. Res., 49, pp. 311-314, 1990.

13. L. Lofgren, M. Larsson, L. Thaning and S. Hallgren, "Transthoracic endoscopic photodynamic treatment of malignant mesothelioma," (letter), The Lancet, 337, p. 359, 1991.

14. H.-B. Riis, HJ. Altermatt, R. Inderbitzi, R. Hess, B. Nachbur, J.C.M. Stewart, Q. Wang, K.C. Lim, R. Bonnett, M.C. Berenbaum and U. Althaus, "Photodynamic therapy with chlorins for diffuse malignant mesothelioma: initial clinical results," Br. J. Cancer, 64, pp. 1116-1120, 1991.

15. H. Heyerdahl, T. Warloe, Q. Peng, K. Svanberg, J. Moan, H.B. Steen, L.O. Svaasand and K.-E. Ciercksky, t¤Dosimetry and light distribution systems for photodynamic lherapy at the Norwegian Radium Hospital," Photodynamic Theragxy of Cancer. G. Jori, J. Moan and W. Star (eds.), pp.27-36, SPIE Vol. 2078, 1993.

16.V.W. Rush, S. Piantadosi and E.C. Holmes, "The role of extrapleural pneumonectomy in malignant pleural mesothelioma," J. Thorac. Cardiovasc. Surg., 102, pp. 1-9, 1991.

17. L.B. Weissmann and K.H. Antman, "Incidence, presentation and promising new treatments for malignant mesothelioma." Oncology Williston Park, 3, pp. 67-72, 1989.

Back to top